Application of Sendai virus

MELTON ONCOLYTIC VIRUS PLATFORM

NDViraFlex™ Engineered Oncolytic Virus Platform

A modular recombinant Newcastle disease virus engineering platform for developing hyperacute rejection–inspired oncolytic viruses, supporting multi-gene payload design, custom vector development, and preclinical evaluation.

Details

Core Technology Platforms

Sendai Virus Vector Engineering Platform

A next-generation Sendai virus vector platform featuring F gene-defective engineering for safe and efficient RNA-based gene delivery. Melton’s Sendai virus platform uses F gene-defective (ΔF) technology to limit viral spread while preserving efficient cytoplasmic RNA delivery. It enables non-integrating, high-efficiency transient gene expression for iPSC reprogramming and customized gene delivery.

Newcastle Disease Virus Engineering Platform

A recombinant Newcastle disease virus platform enabling multi-gene engineering and customized oncolytic virus development. Built on the LaSota strain backbone, Melton s NDV engineering platform supports flexible genetic modification, including multi-cistron payload insertion and specialized functional engineering. The platform provides customized solutions for oncolytic virus research, tumor immunology studies, and preclinical evaluation.

News & events

April.22.2026

Process Optimization of the MeltonVEC™-Cell Fusion Kit (HVJ-E) Product

This process optimization further enhanced product purity. Test results showed that the cell fusion efficiency exceeded 90%, while the issue of high solution viscosity was also significantly improved.

$Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients（Newcastle disease virus with porcine a1,3GT gene ）$

March.26.2025

Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients（Newcastle disease virus with porcine a1,3GT gene ）

This study shows that recombinant NDV-GT, carrying the porcine a1,3GT gene, effectively treats metastatic cancer with a 90% disease control rate in clinical trials, demonstrating high safety, efficacy, and minimal immune response, highlighting its potential as an oncolytic virus therapy.

About OUR COMPANY

Melton Biomedical International Co., Ltd., founded in 2024, is a biotechnology company specializing in paramyxovirus vector technologies.

The company focuses on the development and application of Sendai virus and Newcastle disease virus vector systems for regenerative medicine, vaccine development, and oncology research. With proprietary technologies in engineered and defective paramyxovirus vectors, Melton continues to advance innovative gene delivery and biomedical solutions.

About us: consectetur adipisc ing elit, sed do Eiusmod Tempor inci didunt ut labore et dolore

View More

Contact Us: Shenzhen City ,Guangdong Province, China +86; zhexiao@meltonbiomedtech.com; +86 755-84899046

Melton (Shen Zhen) Biomedical Technology Company Limited